Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Ocular Therapeutix's profit margin for the twelve months ending Jun 30, 2026 was -579.1%. For fiscal 2025 it was -511.9%, against -303.7% the year before. The highest annual figure on record is -15.1% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -511.9% | −208.2 |
| FY2024 | Dec 31, 2024 | -303.7% | −165.5 |
| FY2023 | Dec 31, 2023 | -138.1% | −0.2 |
| FY2022 | Dec 31, 2022 | -138.0% | −122.9 |
| FY2021 | Dec 31, 2021 | -15.1% | +879.2 |
| FY2020 | Dec 31, 2020 | -894.3% | +1149.0 |
| FY2019 | Dec 31, 2019 | -2043.3% | +970.6 |
| FY2018 | Dec 31, 2018 | -3014.0% | +282.2 |
| FY2017 | Dec 31, 2017 | -3296.2% | −927.2 |
| FY2016 | Dec 31, 2016 | -2369.0% | −97.7 |
| FY2015 | Dec 31, 2015 | -2271.3% | +1439.6 |
| FY2014 | Dec 31, 2014 | -3710.9% | +137219.1 |
| FY2012 | Dec 31, 2012 | -140930.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -584.5% | −80.7 |
| Q1 FY2026 | Mar 31, 2026 | -821.6% | −222.9 |
| Q4 FY2025 | Dec 31, 2025 | -488.0% | −204.7 |
| Q3 FY2025 | Sep 30, 2025 | -477.3% | −240.7 |
| Q2 FY2025 | Jun 30, 2025 | -503.9% | −237.6 |
| Q1 FY2025 | Mar 31, 2025 | -598.7% | −159.8 |
| Q4 FY2024 | Dec 31, 2024 | -283.3% | −85.8 |
| Q3 FY2024 | Sep 30, 2024 | -236.6% | −233.2 |
| Q2 FY2024 | Jun 30, 2024 | -266.3% | −130.1 |
| Q1 FY2024 | Mar 31, 2024 | -438.9% | −212.2 |
| Q4 FY2023 | Dec 31, 2023 | -197.4% | −87.0 |
| Q3 FY2023 | Sep 30, 2023 | -3.4% | +198.7 |
| Q2 FY2023 | Jun 30, 2023 | -136.2% | +16.8 |
| Q1 FY2023 | Mar 31, 2023 | -226.7% | −131.6 |
| Q4 FY2022 | Dec 31, 2022 | -110.4% | −79.1 |
| Q3 FY2022 | Sep 30, 2022 | -202.2% | −224.0 |
| Q2 FY2022 | Jun 30, 2022 | -153.0% | −80.6 |
| Q1 FY2022 | Mar 31, 2022 | -95.1% | −137.6 |
| Q4 FY2021 | Dec 31, 2021 | -31.3% | +1133.7 |
| Q3 FY2021 | Sep 30, 2021 | 21.9% | +225.1 |
| Q2 FY2021 | Jun 30, 2021 | -72.4% | +2258.3 |
| Q1 FY2021 | Mar 31, 2021 | 42.5% | +867.0 |
| Q4 FY2020 | Dec 31, 2020 | -1164.9% | −11.7 |
| Q3 FY2020 | Sep 30, 2020 | -203.3% | +2061.9 |
| Q2 FY2020 | Jun 30, 2020 | -2330.7% | +1431.3 |
| Q1 FY2020 | Mar 31, 2020 | -824.5% | +2656.0 |
| Q4 FY2019 | Dec 31, 2019 | -1153.2% | +2298.9 |
| Q3 FY2019 | Sep 30, 2019 | -2265.1% | +748.9 |
| Q2 FY2019 | Jun 30, 2019 | -3762.0% | −1631.8 |
| Q1 FY2019 | Mar 31, 2019 | -3480.5% | +568.0 |
| Q4 FY2018 | Dec 31, 2018 | -3452.2% | −761.8 |
| Q3 FY2018 | Sep 30, 2018 | -3014.1% | −37.6 |
| Q2 FY2018 | Jun 30, 2018 | -2130.2% | +2137.8 |
| Q1 FY2018 | Mar 31, 2018 | -4048.5% | −675.3 |
| Q4 FY2017 | Dec 31, 2017 | -2690.3% | −181.2 |
| Q3 FY2017 | Sep 30, 2017 | -2976.5% | −964.7 |
| Q2 FY2017 | Jun 30, 2017 | -4268.0% | – |
| Q1 FY2017 | Mar 31, 2017 | -3373.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -2509.2% | – |
| Q3 FY2016 | Sep 30, 2016 | -2011.7% | – |
See a number that looks wrong?